Protagonist Therapeutics (PTGX) Enterprise Value (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Enterprise Value of -$547.8 million for Q1 2026, up 4.62% on a YoY basis from -$523.6 million in Q1 2025, and up 3.45% sequentially from -$567.4 million in Q4 2025.
Protagonist Therapeutics (PTGX) Enterprise Value (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Enterprise Value data on file, last reported at -$547.8 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 4.62% year-over-year to -$547.8 million; the trailing twelve-month figure through Mar 2026 stood at -$547.8 million (up 4.62% YoY), and the FY2025 full-year result was -$567.4 million, down 35.44% from the prior year.
- Enterprise Value grew to -$547.8 million in Q1 2026, from -$567.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$120.5 million in Q2 2022 to a low of -$576.1 million in Q3 2025.
- A 5-year average of -$396.9 million and a median of -$341.6 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 37.47% in 2022 and slumped 160.15% in 2023, its largest moves.
- Tracing PTGX's Enterprise Value over 5 years: stood at -$237.3 million in 2022, then tumbled by 43.94% to -$341.6 million in 2023, then decreased by 22.62% to -$418.9 million in 2024, then plunged by 35.44% to -$567.4 million in 2025, then advanced by 3.45% to -$547.8 million in 2026.
- Business Quant data shows PTGX's Enterprise Value at -$547.8 million in Q1 2026, -$567.4 million in Q4 2025, and -$576.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -547.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -547.81 Mn |
| Dec 31, 2025 | -567.39 Mn |
| Sep 30, 2025 | -576.12 Mn |
| Jun 30, 2025 | -570.47 Mn |
| Mar 31, 2025 | -574.35 Mn |
| Dec 31, 2024 | -418.91 Mn |
| Sep 30, 2024 | -468.72 Mn |
| Jun 30, 2024 | -564.00 Mn |
| Mar 31, 2024 | -322.67 Mn |
| Dec 31, 2023 | -341.63 Mn |
| Sep 30, 2023 | -320.75 Mn |
| Jun 30, 2023 | -313.38 Mn |
| Mar 31, 2023 | -230.79 Mn |
| Dec 31, 2022 | -237.34 Mn |
| Sep 30, 2022 | -267.44 Mn |
| Jun 30, 2022 | -120.46 Mn |
| Mar 31, 2022 | -305.29 Mn |
| Dec 31, 2021 | -326.90 Mn |
| Sep 30, 2021 | -314.30 Mn |
| Jun 30, 2021 | -192.64 Mn |